Andrés Yarur

4.4k total citations · 1 hit paper
161 papers, 2.9k citations indexed

About

Andrés Yarur is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Andrés Yarur has authored 161 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 125 papers in Genetics, 98 papers in Epidemiology and 55 papers in Surgery. Recurrent topics in Andrés Yarur's work include Inflammatory Bowel Disease (125 papers), Microscopic Colitis (91 papers) and Eosinophilic Esophagitis (25 papers). Andrés Yarur is often cited by papers focused on Inflammatory Bowel Disease (125 papers), Microscopic Colitis (91 papers) and Eosinophilic Esophagitis (25 papers). Andrés Yarur collaborates with scholars based in United States, Canada and France. Andrés Yarur's co-authors include María T. Abreu, Amar R. Deshpande, Daniel A. Sussman, Maria A. Quintero, Anjali Jain, Frank Czul, David T. Rubin, Jamie S. Barkin, Sharat Singh and David Pechman and has published in prestigious journals such as The Lancet, Gastroenterology and Gut.

In The Last Decade

Andrés Yarur

132 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

2023 190 citations Séverine Vermeire, Laurent Peyrin‐Biroulet et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrés Yarur United States	28	2.1k	1.6k	829	652	283	161	2.9k
Konstantinos Κarmiris Greece	23	2.1k 1.0×	1.7k 1.0×	753 0.9×	708 1.1×	239 0.8×	60	3.2k
Mark T. Osterman United States	31	2.1k 1.0×	1.7k 1.0×	781 0.9×	707 1.1×	517 1.8×	157	3.2k
Henit Yanai Israel	28	1.8k 0.9×	1.3k 0.8×	923 1.1×	600 0.9×	179 0.6×	125	2.6k
Roopal Thakkar United States	29	3.1k 1.5×	2.7k 1.7×	1.5k 1.8×	646 1.0×	346 1.2×	142	5.3k
Parakkal Deepak United States	27	1.4k 0.6×	1.1k 0.7×	832 1.0×	397 0.6×	121 0.4×	209	2.5k
Amanda Ricciuto Canada	17	1.7k 0.8×	1.3k 0.8×	849 1.0×	282 0.4×	145 0.5×	44	2.4k
André D’Hoore Belgium	26	2.2k 1.0×	1.8k 1.1×	1.6k 1.9×	288 0.4×	245 0.9×	77	3.8k
Simone Saibeni Italy	28	1.1k 0.5×	809 0.5×	850 1.0×	299 0.5×	193 0.7×	99	2.3k
Jean Frédéric Colombel France	12	1.6k 0.7×	1.2k 0.8×	690 0.8×	331 0.5×	276 1.0×	14	2.2k
Fraser Cummings United Kingdom	26	1.0k 0.5×	742 0.5×	533 0.6×	791 1.2×	174 0.6×	108	2.3k

Countries citing papers authored by Andrés Yarur

Since Specialization

Citations

This map shows the geographic impact of Andrés Yarur's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrés Yarur with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrés Yarur more than expected).

Fields of papers citing papers by Andrés Yarur

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrés Yarur. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrés Yarur. The network helps show where Andrés Yarur may publish in the future.

Co-authorship network of co-authors of Andrés Yarur

This figure shows the co-authorship network connecting the top 25 collaborators of Andrés Yarur. A scholar is included among the top collaborators of Andrés Yarur based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrés Yarur. Andrés Yarur is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vermeire, Séverine, David T. Rubin, Laurent Peyrin-Biroulet, et al.. (2025). Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis. BMJ Open Gastroenterology. 12(1). e001516–e001516. 6 indexed citations

Alayo, Quazim A., Andrés Yarur, Deborah A. Thomas, et al.. (2025). Systematic Review With Meta-Analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Diseases. Inflammatory Bowel Diseases. 32(1). 39–52.

Yarur, Andrés, Thierry Dervieux, Ryan C. Ungaro, et al.. (2025). Ustekinumab Drug Clearance Is Better Associated with Disease Control than Serum Trough Concentrations in a Prospective Cohort of Inflammatory Bowel Disease. Pharmaceutics. 17(2). 187–187.

Vermeire, Séverine, Marla Dubinsky, Brian Feagan, et al.. (2024). P113 Maintenance of week 12 response through week 52 with etrasimod in patients with ulcerative colitis in ELEVATE UC 52. Poster presentations. A119.1–A119.

Yarur, Andrés, Stephen B. Hanauer, Jean‐Frédéric Colombel, et al.. (2024). Su1755 IMPACT OF BODY MASS INDEX ON CLINICAL OUTCOMES AND DRUG LEVELS IN PATIENTS WITH CROHN'S DISEASE RECEIVING MAINTENANCE TREATMENT WITH SUBCUTANEOUS INFLIXIMAB: A POST HOC ANALYSIS OF THE LIBERTY-CD STUDY. Gastroenterology. 166(5). S–798. 2 indexed citations

Yarur, Andrés, et al.. (2024). Managing Risks with Newer Oral Small Molecules in Patients with Inflammatory Bowel Diseases. Current Gastroenterology Reports. 26(5). 145–156. 2 indexed citations

Peyrin‐Biroulet, Laurent, Marla C. Dubinsky, Bruce E. Sands, et al.. (2024). Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme. Journal of Crohn s and Colitis. 18(8). 1270–1282. 16 indexed citations

Jaber, Fouad, Saqr Alsakarneh, Poonam Beniwal‐Patel, et al.. (2024). Predictive Factors of Non-Inflammatory Small Bowel Obstruction After Bowel Resection in Crohn’s Patients. Gastroenterology Research. 17(2). 64–71.

Yarur, Andrés, Stephen B. Hanauer, Stefan Schreiber, et al.. (2024). P1074 Impact of body mass index (BMI) on clinical outcomes and drug levels in patients with Crohn’s disease receiving maintenance treatment with subcutaneous infliximab: A post hoc analysis of the LIBERTY-CD study. Journal of Crohn s and Colitis. 18(Supplement_1). i1921–i1922. 1 indexed citations

10.

Peyrin‐Biroulet, Laurent, Marla C. Dubinsky, B E Sands, et al.. (2023). P407 Efficacy and safety of etrasimod in subjects with moderately to severely active isolated proctitis: a subgroup analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials. Journal of Crohn s and Colitis. 17(Supplement_1). i536–i538. 4 indexed citations

11.

Núñez, Paulina, et al.. (2023). Current perspectives on pediatric inflammatory bowel disease focusing on transitional care management. What should we consider?. Gastroenterología y Hepatología (English Edition). 46(2). 139–147.

12.

Vermeire, Séverine, B E Sands, Marla C. Dubinsky, et al.. (2023). P582 Efficacy of etrasimod at week 52 among subjects who reached clinical response at week 12: post hoc analysis of the phase 3 ELEVATE UC 52 trial. Journal of Crohn s and Colitis. 17(Supplement_1). i709–i711. 3 indexed citations

13.

Yarur, Andrés, Parakkal Deepak, Poonam Beniwal‐Patel, et al.. (2023). Tu1750 A HIGHER VISCERAL ADIPOSE TISSUE BURDEN IS ASSOCIATED WITH HIGHER INFLIXIMAB CLEARANCE IN INFLAMMATORY BOWEL DISEASE. Gastroenterology. 164(6). S–1109.

14.

Verstockt, Bram, Séverine Vermeire, Laurent Peyrin‐Biroulet, et al.. (2023). The Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study. Journal of Crohn s and Colitis. 18(5). 762–772. 6 indexed citations

15.

Dulai, Parambir S., Victoria Rai, Laura E. Raffals, et al.. (2022). Recommendations on the Appropriate Management of Steroids and Discharge Planning During and After Hospital Admission for Moderate-Severe Ulcerative Colitis: Results of a RAND Appropriateness Panel. The American Journal of Gastroenterology. 117(8). 1288–1295. 5 indexed citations

16.

Hemperly, Amy, Marla C. Dubinsky, Andrés Yarur, et al.. (2021). Noninvasive Targeted Crohn Disease Management by Combining Endoscopic Healing Index and Therapeutic Drug Monitoring. Crohn s & Colitis 360. 3(3). otab035–otab035. 1 indexed citations

17.

Christensen, Britt, Dejan Micić, Peter G. Gibson, et al.. (2018). Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Alimentary Pharmacology & Therapeutics. 47(6). 753–762. 59 indexed citations

18.

Yarur, Andrés, Vikram Kanagala, Dan J. Stein, et al.. (2017). Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease. Alimentary Pharmacology & Therapeutics. 45(7). 933–940. 210 indexed citations

19.

Yarur, Andrés, et al.. (2014). The incidence and risk factors for developing depression after being diagnosed with inflammatory bowel disease: a cohort study. Alimentary Pharmacology & Therapeutics. 39(8). 802–810. 121 indexed citations

20.

Yarur, Andrés, et al.. (2009). "Síndrome pequeño para su tamaño", (small-for-size), como complicación de un trasplante hepático con donante vivo adulto relacionado. Revista médica de Chile. 137(7). 918–22. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact